Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Innate Pharma S.A. Sponsored ADR IPHA

Healthcare  —  Biotechnology
1.70 0.00 0.00% as of 25 Sep
Market cap
$188.8M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Innate Pharma S.A. Sponsored ADR (IPHA) Business Profile

Updated before January 2025

Company Overview

Innate Pharma S.A. Sponsored ADR (IPHA) is a clinical-stage biotechnology company headquartered in Marseille, France. Founded in 1999, the company specializes in the development of immunotherapies aimed at harnessing the innate immune system to treat cancer and inflammatory diseases. Innate Pharma operates with a mission to improve patient outcomes by leveraging its expertise in immunology and antibody engineering. The company is publicly traded on the NASDAQ under the ticker symbol IPHA. Key leadership includes Mondher Mahjoubi, who serves as the Chief Executive Officer, and Hervé Brailly, one of the co-founders and a key figure in the company’s early development.

Innate Pharma has established itself as a pioneer in the field of immuno-oncology, focusing on innovative therapies that target natural killer (NK) cells and other components of the innate immune system. Over the years, the company has formed strategic partnerships with leading pharmaceutical companies such as AstraZeneca and Sanofi, further solidifying its position in the biotechnology sector.

Core Business Segments

Innate Pharma’s business is primarily divided into the following core segments:

1. Immuno-Oncology Therapeutics

This segment focuses on developing monoclonal antibodies and other biologics that enhance the immune system’s ability to fight cancer. Key products and candidates include:

  • Monalizumab: A first-in-class immune checkpoint inhibitor targeting NKG2A receptors on NK and T cells. Monalizumab is being developed in collaboration with AstraZeneca and is currently in clinical trials for various cancers, including head and neck squamous cell carcinoma.
  • Lacutamab: A monoclonal antibody targeting KIR3DL2, primarily developed for the treatment of cutaneous T-cell lymphoma (CTCL).
  • IPH5201: An anti-CD39 antibody developed in partnership with AstraZeneca, aimed at enhancing anti-tumor immunity by modulating the adenosine pathway.

2. Inflammatory Disease Therapies

Innate Pharma is also exploring the potential of its immunotherapy platform to address inflammatory and autoimmune diseases. While this segment is still in its early stages, it represents a promising area for future growth.

3. Proprietary Antibody Engineering Platform

The company has developed a proprietary technology platform for engineering antibodies that target specific immune pathways. This platform underpins many of its current and future product candidates, enabling Innate Pharma to maintain a robust pipeline of innovative therapies.

Business Model

Innate Pharma operates on a hybrid business model that combines in-house drug development with strategic partnerships. The company generates revenue through:

  • Collaborations and Licensing Agreements: Partnerships with pharmaceutical giants like AstraZeneca and Sanofi provide upfront payments, milestone payments, and royalties on sales of co-developed products.
  • Government Grants and Subsidies: As a European biotech company, Innate Pharma benefits from various government funding programs that support research and development.
  • Equity Financing: The company raises capital through public and private equity offerings to fund its clinical trials and pipeline expansion.

This diversified revenue model allows Innate Pharma to mitigate risks associated with the high costs and uncertainties of drug development.

Strategic Direction

Innate Pharma’s strategic priorities include:

  • Pipeline Expansion: The company aims to advance its existing clinical candidates while exploring new targets within the innate immune system.
  • Geographic Expansion: Innate Pharma is focused on increasing its presence in key markets, particularly in North America and Asia.
  • Sustainability Goals: The company is committed to sustainable practices in its operations, including reducing its carbon footprint and promoting ethical clinical trial practices.
  • Innovation in Immunotherapy: Innate Pharma continues to invest in cutting-edge research to develop next-generation immunotherapies that address unmet medical needs.

Competitive Landscape

Innate Pharma operates in a highly competitive biotechnology sector, with key competitors including:

  • Genmab: A Danish biotech company specializing in antibody therapeutics.
  • Immunocore: A UK-based company focused on T-cell receptor therapies.
  • MacroGenics: A U.S.-based biotech firm developing monoclonal antibodies for cancer and autoimmune diseases.
  • Adaptimmune: Another UK-based company working on T-cell therapies for cancer.

Despite the competition, Innate Pharma differentiates itself through its focus on the innate immune system and its strong partnerships with established pharmaceutical companies.

Risk Factors

Innate Pharma faces several risks, including:

  • Clinical Trial Risks: The success of the company’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Navigating the complex regulatory landscape for drug approval can delay product launches.
  • Market Dependence: The company relies heavily on its partnerships for revenue, making it vulnerable to changes in these relationships.
  • Supply Chain Disruptions: Global supply chain issues could impact the availability of raw materials and manufacturing processes.

Recent Developments

  • Monalizumab Clinical Trials: Recent data from Phase II trials have shown promising results, paving the way for further development in collaboration with AstraZeneca.
  • New Partnerships: Innate Pharma recently announced a collaboration with a leading biotech company to explore new targets in immuno-oncology.
  • COVID-19 Impact: The pandemic has had a mixed impact, delaying some clinical trials while accelerating interest in immunotherapies.

Investment Considerations

Strengths:

  • Strong pipeline of innovative therapies.
  • Strategic partnerships with industry leaders.
  • Proprietary antibody engineering platform.

Risks:

  • High dependence on clinical trial outcomes.
  • Competitive market landscape.
  • Financial risks associated with early-stage biotech companies.

Conclusion

Innate Pharma S.A. is a leading player in the field of immuno-oncology, with a robust pipeline and strong industry partnerships. While the company faces challenges typical of the biotech sector, its focus on the innate immune system and commitment to innovation position it well for future growth. Investors should weigh the company’s strengths against its risks to make informed decisions about its potential as an investment opportunity.